Table 3.
Baseline characteristics based on oligo-progression.
| Oligo-progression | Multiple progression | P-value | |
|---|---|---|---|
| (Progression site 1–2) | (Progression site 3 ≤) | ||
| (n = 52) | (n = 11) | ||
| Age (years) | |||
| Median (range) | 64 (34–84) | 62 (49–74) | 0.752 |
| Sex | |||
| Male | 38 (73.1) | 9 (81.8) | 0.714 |
| Female | 14 (26.9) | 2 (18.2) | |
| Smoking | |||
| Never smoked | 19 (36.5) | 2 (18.2) | 0.31 |
| Current or ex-smoker | 33 (63.5) | 9 (81.8) | |
| Pathology | |||
| Squamous | 16 (30.8) | 3 (27.3) | 0.822 |
| Non-Squamous | 36 (69.2) | 8 (62.7) | |
| ICI treatment line | |||
| 01-Feb | 40 (76.9) | 7 (63.6) | 0.449 |
| 3 ≤ | 12 (23.1) | 4 (36.4) | |
| Monotherapy | |||
| PD-1 inhibitor | 27 (51.9) | 9 (81.8) | |
| PD-L1 inhibitor | 16 (30.8) | 0 (0) | |
| Combination therapy | |||
| PD-1 inhibitor + chemotherapy | 1 (1.9) | 0 (0) | |
| PD-1 inhibitor + CTLA-4 inhibitor | 3 (5.8) | 2 (18.2) | |
| PD-L1 inhibitor + CTLA-4 inhibitor | 5 (9.6) | 0 (0.0) | |
| Previous response | |||
| SD | 29 (55.8) | 8 (72.7) | 0.502 |
| PR | 23 (44.2) | 3 (27.3) | |
| Progression sitea | |||
| Lung | 28 (53.8) | 10 (90.9) | 0.039 |
| Non-lung visceral organ | |||
| Liver | 2 (3.8) | 2 (18.2) | 0.275 |
| Colon | 1 (1.9) | 0 (0) | |
| Adrenal gland | 1 (1.9) | 0 (0) | |
| Heart (pericardium) | 1 (1.9) | 1 (9.1) | |
| Brain | 5 (9.6) | 1 (9.1) | 1 |
| Bone | 1 (1.9) | 3 (27.3) | 0.015 |
| Lymph node | 14 (23.6) | 11 (100) | < 0.001 |
| Neck | 3 (5.8) | 1 (9.1) | |
| Axilla | 1 (1.9) | 1 (9.1) | |
| Thoracic | 10 (15.9) | 10 (90.9) | |
| Abdomen | 4 (6.3) | 0 (0) | |
| Pre-existence of progression site | |||
| New only | 12 (23.1) | 0 (0) | < 0.001 |
| Existing only | 39 (75.0) | 5 (45.5) | |
| Both new and existing | 1 (1.9) | 6 (54.5) | |
| Pattern of progression sites | |||
| Lymph node only | 14 (27.0) | 0 (0) | 0.103 |
| Extranodal organs | 38 (73.0) | 11 (100.0) |
Bold values denote statistical significance at the p < 0.05 level
PR partial response, SD stable disease, PD-1 programmed death 1, PD-L1 programmed death ligand 1, CTLA-4 Cytotoxic T-Lymphocyte Associated Protein 4.
aPatients can be included in more than one group based on the site of progression13.